Elevar Therapeutics Announces Camrelizumab Plus Rivoceranib Significantly Prolonged Overall Survival and Progression-Free Survival Versus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma During Phase 3 Trial, a Joint Program With Hengrui Pharma
September 10, 2022 04:00 ET
|
Elevar Therapeutics
Top-line findings were presented today at the annual European Society for Medical Oncology (ESMO) Congress This is the first positive pivotal trial to show survival benefits with a PD-1 inhibitor...
Elevar Therapeutics Announces Camrelizumab Plus Rivoceranib Significantly Prolonged Overall Survival and Progression-Free Survival Versus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma During Phase 3 Trial, a Joint Program With Hengrui Pharma
September 07, 2022 18:05 ET
|
Elevar Therapeutics
Top-line findings will be presented Sept. 10 at the annual European Society for Medical Oncology (ESMO) Congress This is the first positive pivotal trial to show survival benefits with a PD-1...
'I Can't Wait' is the Campaign Theme for World Hepatitis Day 2022
July 28, 2022 00:15 ET
|
World Hepatitis Alliance
LONDON, England, July 28, 2022 (GLOBE NEWSWIRE) -- Today, World Hepatitis Day (WHD) launches with the campaign theme 'I Can't Wait'. On WHD, the World Hepatitis Alliance (WHA) joins together with...
Liver Cancer Pipeline Insight | Clinical Trial Research Evaluation Report
July 25, 2022 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, July 25, 2022 (GLOBE NEWSWIRE) -- Liver Cancer Pipeline Insight | Clinical Trial Research Evaluation Report DelveInsight’s liver cancer pipeline report depicts a robust space with...
Epirubicin Market Worth $243.99 Million, Globally, by 2028 at 3.6% CAGR - Exclusive Report by The Insight Partners
July 22, 2022 06:56 ET
|
The Insight Partners
New York, July 22, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Epirubicin Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Dosage (10mg/Vial,...
Provectus Biopharmaceuticals Presents Data from PV-10® Treatment of Metastatic Uveal Melanoma Patients in Two Oral Presentations at 2022 International Society of Ocular Oncology (ISOO) Congress
June 30, 2022 13:42 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, June 30, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that updated data from the Company’s initial expansion cohort of patients with uveal melanoma metastatic to...
Provectus Biopharmaceuticals Presents Multiple Metabolic Complete Responders from PV-10® Treatment of Early-Stage Metastatic Uveal Melanoma Patients at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
June 08, 2022 07:00 ET
|
Provectus Biopharmaceuticals Inc.
29% of M1a patients achieved metabolic complete response (mCR)mCR patients alive up to >4 years after start of PV-10 treatmentPET tumor response assessment more accurate than 2D EASL or...
Outpatient Oncology Infusion Market worth USD 162.4 Billion by 2030, Says Global Market Insights Inc.
May 23, 2022 05:15 ET
|
Global Market Insights Inc.
Selbyville, Delaware, May 23, 2022 (GLOBE NEWSWIRE) -- The outpatient oncology infusion market value is projected to reach USD 162.4 billion by 2030, according to a new research report by Global...
Provectus Biopharmaceuticals Announces Acceptance of PV-10® Immunotherapy Abstract for Metastatic Uveal Melanoma at American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
April 27, 2022 10:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, April 27, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of investigational cancer immunotherapy PV-10, a formulation of...
Liver Cancer Diagnostics Market Worth $15.95Bn, Globally, by 2028 at 8% CAGR - Exclusive Report by The Insight Partners
April 07, 2022 10:50 ET
|
The Insight Partners
New York, April 07, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Liver Cancer Diagnostics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type...